Strati Areti, Economopoulou Panagiota, Lianidou Evi, Psyrri Amanda
Analysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
Department of Internal Medicine, Section of Medical Oncology, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece.
Biomedicines. 2023 Jun 20;11(6):1768. doi: 10.3390/biomedicines11061768.
The approval of monoclonal antibodies against programmed death-ligand 1 (PD-L1) and programmed cell death protein (PD1) has changed the landscape of cancer treatment. To date, many immune checkpoint inhibitors (ICIs) have been approved by the FDA for the treatment of metastatic cancer as well as locally recurrent advanced cancer. However, immune-related adverse events (irAEs) of ICIs highlight the need for biomarker analysis with strong predictive value. Liquid biopsy is an important tool for clinical oncologists to monitor cancer patients and administer or change appropriate therapy. CTCs frequently express PD-L1, and this constitutes a clinically useful and non-invasive method to assess PD-L1 status in real-time. This review summarizes all the latest findings about the clinical significance of CTC for the management of cancer patients during the administration of immunotherapy and mainly focuses on the assessment of PD-L1 expression in CTCs.
抗程序性死亡配体1（PD-L1）和程序性细胞死亡蛋白（PD1）单克隆抗体的获批改变了癌症治疗格局。迄今为止，许多免疫检查点抑制剂（ICI）已获美国食品药品监督管理局（FDA）批准用于治疗转移性癌症以及局部复发的晚期癌症。然而，ICI的免疫相关不良事件（irAE）凸显了对具有强大预测价值的生物标志物分析的需求。液体活检是临床肿瘤学家监测癌症患者并实施或更改适当治疗的重要工具。循环肿瘤细胞（CTC）经常表达PD-L1，这构成了一种实时评估PD-L1状态的临床有用且非侵入性的方法。本综述总结了关于CTC在免疫治疗期间对癌症患者管理的临床意义的所有最新发现，并且主要聚焦于对CTC中PD-L1表达的评估。
